Patent Document ID: 9890430
Application ID: 14407913
Patent Flag: 1

Claim One:
1. A method of predicting the likelihood of long-term survival without recurrence of cancer for a subject having estrogen receptor positive (ER+) breast cancer treated with endocrine monotherapy, the method comprising: a) obtaining a breast cancer tissue sample from a human subject; b) generating cDNA from the sample; c) detecting expression levels of a set of genes consisting of (i) endocrine therapy sensitivity genes PARP3, AZGP1, EPHX2, IGFBP4, NUDT18, FOM5, C1orf66, COL14A1, PLAT, PCM1, ABTB20, NFKB1, TK2, ABAT, ANF18, PHYHD1, and CHDH and (ii) endocrine monotherapy resistance genes CENPE, CCNB1, KIFC1, CCT6A, EIF2C2, RAD54B, VDAC2, MCM10, ZWINT, KIF18A, RACGAP1, TDG, NUP107, TMPO, XPOT, BIRC5, TOP2A, DSC2, EIP2S2, UBEC2C, TPX2, C20orf24, KIF4A, CDC2, CDCA5, C8orf76, and FBXO45 from the cDNA; and d) assigning the subject to a sensitive, indeterminate or resistant group, wherein assignment to the sensitive group predicts longer relapse-free survival compared to the resistant group, wherein the assigning the subject to a sensitive, indeterminate or resistant group comprises determining the gene centroid of the endocrine therapy sensitivity genes and the gene centroid of the endocrine therapy resistance genes.